Literature DB >> 8044069

Bilateral cataracts and glaucoma induced by long term use of steroid eye drops.

J M Butcher1, M Austin, J McGalliard, R D Bourke.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1994        PMID： 8044069      PMCID： PMC2542608          DOI： 10.1136/bmj.309.6946.43

Source DB:  PubMed          Journal:  BMJ        ISSN： 0959-8138


× No keyword cloud information.
  9 in total

1.  STATISTICAL ATTRIBUTES OF THE STEROID HYPERTENSIVE RESPONSE IN THE CLINICALLY NORMAL EYE. I. THE DEMONSTRATION OF THREE LEVELS OF RESPONSE.

Authors:  M F ARMALY
Journal:  Invest Ophthalmol       Date:  1965-04

2.  Cortisone and hydrocortisone in ocular infections.

Authors:  P THYGESON; M J HOGAN; S J KIMURA
Journal:  Trans Am Acad Ophthalmol Otolaryngol       Date:  1953 Jan-Feb

3.  Use of steroid eye drops in general practice.

Authors:  M J Lavin; G E Rose
Journal:  Br Med J (Clin Res Ed)       Date:  1986-05-31

4.  Steroids, the eye, and general practitioners.

Authors:  D St Clair Roberts
Journal:  Br Med J (Clin Res Ed)       Date:  1986-05-31

5.  Ocular side effects of systemic steroid therapy in renal transplant patients.

Authors:  S C Debnath; M S Abomelha; M Jawdat; R Chang; A A Al-Khader
Journal:  Ann Ophthalmol       Date:  1987-11

Review 6.  Ocular effects of topical and systemic steroids.

Authors:  L Renfro; J S Snow
Journal:  Dermatol Clin       Date:  1992-07       Impact factor: 3.478

Review 7.  Corticosteroid-induced cataracts.

Authors:  R C Urban; E Cotlier
Journal:  Surv Ophthalmol       Date:  1986 Sep-Oct       Impact factor: 6.048

8.  Relationship of steroid dose to degree of posterior subcapsular cataracts in nephrotic syndrome.

Authors:  S R Limaye; S Pillai; L U Tina
Journal:  Ann Ophthalmol       Date:  1988-06

9.  Risk factors for the development of posterior subcapsular cataracts in patients with cystic fibrosis and allergic bronchopulmonary aspergillosis treated with corticosteroids.

Authors:  M Majure; S Mroueh; A Spock
Journal:  Pediatr Pulmonol       Date:  1989
  9 in total
  14 in total

1.  Treatment of presumed trematode-induced granulomatous anterior uveitis among children in rural areas of Egypt.

Authors:  Amgad El Nokrashy; Waleed Abou Samra; Doaa Sobeih; Ali Lamin; Aya Hashish; Sahar Tarshouby; Susan Lightman; Ashraf Sewelam
Journal:  Eye (Lond)       Date:  2019-04-03       Impact factor: 3.775

2.  Topical steroids for ocular disease.

Authors:  N Rowson
Journal:  BMJ       Date:  1994-09-17

3.  Periocular steroid ointments may cause ocular damage.

Authors:  C J McLean; R F Lobo; D J Brazier
Journal:  BMJ       Date:  1994 Aug 20-27

4.  Glaucoma induced by steroids.

Authors:  N H Chong
Journal:  BMJ       Date:  1994-07-30

5.  Corticosteroids and open-angle glaucoma in the elderly: a population-based cohort study.

Authors:  Michael W Marcus; Rogier P H M Müskens; Wishal D Ramdas; Roger C W Wolfs; Paulus T V M De Jong; Johannes R Vingerling; Albert Hofman; Bruno H C Stricker; Nomdo M Jansonius
Journal:  Drugs Aging       Date:  2012-12       Impact factor: 3.923

6.  Some blood plasma constituents correlate with human cataract.

Authors:  C A Donnelly; J Seth; R M Clayton; C I Phillips; J Cuthbert; R J Prescott
Journal:  Br J Ophthalmol       Date:  1995-11       Impact factor: 4.638

7.  [Antiangiogenic therapy for pterygium recurrence].

Authors:  S Leippi; F Grehn; G Geerling
Journal:  Ophthalmologe       Date:  2009-05       Impact factor: 1.059

8.  Diabetic macular edema: therapeutic options.

Authors:  Amol D Kulkarni; Michael S Ip
Journal:  Diabetes Ther       Date:  2012-03-06       Impact factor: 2.945

9.  Clinical applications of the sustained-release dexamethasone implant for treatment of macular edema.

Authors:  Rocío Herrero-Vanrell; Jose Augusto Cardillo; Baruch D Kuppermann
Journal:  Clin Ophthalmol       Date:  2011-02-01

Review 10.  The Role of Alpha-MSH as a Modulator of Ocular Immunobiology Exemplifies Mechanistic Differences between Melanocortins and Steroids.

Authors:  Christine M Clemson; John Yost; Andrew W Taylor
Journal:  Ocul Immunol Inflamm       Date:  2016-01-25       Impact factor: 3.070
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.